(lp0
S'Lexicon Pharmaceuticals Inc Realized Volatility Hits A Weakened Level CML News - 13 hours ago This is a proprietary realized volatility rating created by Capital Market Laboratories  based on a large number of data interactions for Lexicon Pharmaceuticals Inc  . We examine the little used gem of daily stock volatility over ...'
p1
aS'Earnings Reaction History: Lexicon Pharmaceuticals Inc., 33.3% Follow-Through ... Nasdaq - Mar 3, 2017 Lexicon Pharmaceuticals Inc.  is due to issue its quarterly earnings report in the upcoming extended-hours session.'
p2
aS'The Long Case For Lexicon Pharmaceuticals Seeking Alpha - Feb 16, 2017 Lexicon Pharmaceuticals  is about to become a commercial stage company. The PDUFA date for telotristat ethyl  is on February 28, with a high likelihood of approval.'
p3
aS'Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 ... PR Newswire  - Mar 3, 2017 THE WOODLANDS, Texas, March 3, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. , today reported financial results for the three months and year ended December 31, 2016 and provided an overview of key milestones for the&nbsp;...Lexicon Pharmaceuticals Inc.  Moves Lower on Volume Spike for March 02 - Equities.com'
p4
aS"FDA OKs Lexicon Pharma's telotristat etiprate for carcinoid syndrome Seeking Alpha - Feb 28, 2017 The FDA approves Lexicon Pharmaceuticals'  XERMELO  250 mg for the treatment of carcinoid syndrome diarrhea, in combination with somatostatin therapy  in adult patients inadequately controlled with SSA therapy.FDA approves Lexicon Pharma's carcinoid syndrome diarrhea drug - ReutersLexicon Pharma  Announces FDA Approval for XERMELO to Treat Carcinoid ... - StreetInsider.com"
p5
aS'Lexicon Pharmaceuticals Inc.  Moves Higher on Volume Spike for February 27 Equities.com - Feb 27, 2017 Lexicon Pharmaceuticals Inc.  traded on unusually high volume on Feb. 27, as the stock gained 4.64% to close at $16.45.Lexicon Pharmaceuticals  Stock: FDA Approves XERMELO - CNA Finance '
p6
aS'Lexicon To Present At The Barclays Global Healthcare Conference PR Newswire  - Mar 9, 2017 Lexicon Pharmaceuticals, Inc.  announced today that Lexicon management will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2017 at 3:50 p.m.'
p7
aS'Estimating the intrinsic value of Lexicon Pharmaceuticals Inc  Simply Wall St - Mar 3, 2017 How far off is Lexicon Pharmaceuticals  to its intrinsic value? I am going to take a look now using a method called discounted cash flow or DCF.'
p8
aS'Lexicon: Xermelo Approved, Provides Valuation Floor Seeking Alpha - Mar 7, 2017 Lexicon  announced the approval of telotristat ethyl  last week. The stock briefly touched $18 in after-hours trading yesterday and closed below $16 today.'
p9
aS'Lexicon To Present At The Cowen And Company 37th Annual Healthcare Conference PR Newswire  - Mar 6, 2017 THE WOODLANDS, Texas, March 6, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc.  announced today that Lexicon management will present at the Cowen and Company 37th Annual Healthcare Conference on Wednesday, March 8,&nbsp;...'
p10
a.